z-logo
open-access-imgOpen Access
Percentage of tumor-infiltrating lymphocytes after chemoradiation therapy for locally advanced esophageal squamous cell carcinoma: a biomarker for pathological response rates and cancer-specific survival?
Author(s) -
Shawn S. Groth,
Bryan M. Burt
Publication year - 2019
Publication title -
annals of translational medicine
Language(s) - English
Resource type - Journals
eISSN - 2305-5847
pISSN - 2305-5839
DOI - 10.21037/atm.2019.10.25
Subject(s) - pathological , medicine , biomarker , esophageal cancer , esophageal squamous cell carcinoma , oncology , carcinoma , chemoradiotherapy , pathology , cancer , basal cell , radiation therapy , cancer research , biology , biochemistry
Both the innate and adaptive immune systems play a central role in the surveillance and control of neoplasia. A source of much recent attention, tumor infiltrating lymphocytes (TILs) are a population of T-cells, which have a greater degree of immunological reactivity against neoplastic cells, as compared with circulating (non-tumor infiltrating) lymphocytes. Given the key role that they play, TILs have been explored as prognostic biomarkers for a number of solid organ malignancies, including breast cancer (1), head and neck cancers (2), melanoma (3), colorectal cancer (4), non-small cell lung cancer (5), malignant pleural mesothelioma (6), and esophageal cancer (7).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom